A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of AMG 479 or Placebo in Combination With Gemcitabine as First-line Therapy for Locally Advanced Unresectable Adenocarcinoma of the Pancreas.

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of AMG 479 or Placebo in Combination With Gemcitabine as First-line Therapy for Locally Advanced Unresectable Adenocarcinoma of the Pancreas.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Ganitumab (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 05 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
    • 08 Aug 2012 Status changed from recruiting to discontinued.
    • 21 Jul 2012 Additional lead trial investigator (David Cunningham) identified as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top